TEVA

Announcements

Nothing here yet

Daily updates

• Teva received FDA approval for WELTRUZA (olanzapine) extended-release injectable suspension, a once-monthly subcutaneous long-acting treatment for schizophrenia in adults.Oct 9, 2026
• TEV ‘408 met the primary endpoint in Phase 2a celiac disease trialSep 2, 2026

FDA designations

• Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System AtrophySep 9, 2025

News

• Teva receives FDA approval for WELTRUZA (olanzapine) extended-release injectable suspension, the first and only once-monthly subcutaneous olanzapine for adults with schizophreniaOct 9, 2026
• Teva highlights a Journal of Child Neurology review on dopamine's role in Tourette syndrome and ecopipam's selective D1 receptor mechanism in pediatric patientsOct 4, 2026
• Teva presents new efficacy and safety data for investigational ecopipam in pediatric patients with Tourette syndromeOct 2, 2026
• Teva reported post hoc data for its once-monthly subcutaneous olanzapine LAI TEV-'749 showing high stabilization rates and durable efficacy in adults with schizophreniaSep 19, 2026
• Teva highlighted real-world data showing UZEDY outperformed other long-acting injectables in treatment persistence while reducing emergency care and healthcare costs in schizophreniaSep 19, 2026